The study aimed to investigate the clinical significance of serum cytokine-induced apoptosis inhibitor 1 (CIAPIN1) and its potential impact on cardiac dysfunction and inflammatory response induced by sepsis. A cross-sectional study was conducted in an intensive care unit (ICU) involving 80 healthy individuals and 95 severe sepsis patients. The data were analyzed to establish the correlation between CIAPIN1 levels and the onset of cardiac dysfunction in patients with sepsis. The associations have been established by the Pearson correlation test, one-way ANOVA, Bonferroni post hoc test, and plotting the receiver operating characteristic (ROC). H9c2 cells were treated with LPS (1 μg/mL) for 24 h to establish an in vitro model of septic cardiomyopathy. Meanwhile, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) were detected by enzyme-linked immunosorbent assay (ELISA). Serum CIAPIN1 levels were considerably lower in sepsis patients with cardiac dysfunction. CIAPIN1 expression levels were negatively correlated with TNF-α (r = -0.476, P<0.001), IL-1β (r = -0.584, P<0.001), IL-6 (r = -0.618, P<0.001), creatine kinase- MB (CK-MB) (r = -0.454, P<0.001), and high-sensitive cardiac troponin T (hs-cTnT) (r = -0.586, P<0.001). The ROC curve showed that CIAPIN1 significantly identify sepsis patients from healthy individuals. CIAPIN1 knockdown decreases cardiomyocyte proliferation and increases apoptosis induced by LPS. In addition, CIAPIN1 knockdown reduced cardiac dysfunction and increased inflammatory response in H9c2 rat cardiomyocytes. CIAPIN1 could be a potential biomarker for detecting sepsis patients and suppressing CIAPIN1 expression in H9c2 rat cardiomyocytes, attenuating sepsis-induced cardiac dysfunction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.peptides.2024.171295 | DOI Listing |
Background: The new anti-Aβ antibody drugs aducanumab and lecanemab (approved in the US, not yet in Europe) must be followed up closely and regularly long-term. Previous knowledge on progression of AD in routine clinical settings longterm is crucial when introducing new dementia medications. The Swedish national quality database on dementia/cognitive disorders, SveDem, where data on different dementia disorders at the time of the dementia diagnosis since 2007 and on mild cognitive impairment (MCI) since 2021 with annual follow-ups of MMSE scores can provide this unique information.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Yale School of Public Health, New Haven, CT, USA.
Background: The Republic of Armenia is a post-Soviet, low- and middle-income country (LMIC) in the south Caucasus region with a steadily increasing aging population. The goal of this study was to provide the first look into the national cognitive health in Armenia, considering the growing burden of cognitive impairment (CI) and widespread lack of public awareness about dementia. As a component of the early detection memory screening program launched by Alzheimer's Care Armenia's Brain Health Project and funded through Davos Alzheimer's Collaborative (DAC), this study aimed to understand the prevalence of CI and associated factors across the adult population.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
VA Boston Healthcare System, Jamaica Plain, MA, USA.
Background: Mixed dementia type - Alzheimer's Disease (AD), cerebral amyloid angiopathy (CAA), and vascular - is vastly recognized as a cause of dementia in older adults. Whereas CAA, primarily leptomeningeal, is a frequent complication in hereditary transthyretin cardiac amyloidosis (TTRCA), it is unusually reported in association with wild-type TTR, with or without polyneuropathy. The knowledge of mixed dementia and wild-type TTR association is even scarcer.
View Article and Find Full Text PDFThe recent ACHIEVE study (https://www.achievestudy.org/) demonstrated the substantial benefit of hearing aid use in those with mild-moderate hearing loss and at increased risk for cognitive decline.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Laboratory of Neuro Imaging (LONI), University of Southern California, Los Angeles, CA, USA.
Background: Anti-amyloid therapy appears to have an increased effect on reducing cognitive decline in amyloid- and tau-positive individuals. However, clinical trials inclusion criteria require solely amyloid positivity. Herein, we developed a machine-learning prediction model to identify tau positivity in amyloid-positive individuals using clinical variables.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!